CA3025019A1 - Use of glutamate modulating agents with immunotherapies to treat cancer - Google Patents

Use of glutamate modulating agents with immunotherapies to treat cancer Download PDF

Info

Publication number
CA3025019A1
CA3025019A1 CA3025019A CA3025019A CA3025019A1 CA 3025019 A1 CA3025019 A1 CA 3025019A1 CA 3025019 A CA3025019 A CA 3025019A CA 3025019 A CA3025019 A CA 3025019A CA 3025019 A1 CA3025019 A1 CA 3025019A1
Authority
CA
Canada
Prior art keywords
cancer
antibody
glutamate
agent
immunotherapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3025019A
Other languages
English (en)
French (fr)
Inventor
Vladimir Coric
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biohaven Pharmaceutical Holding Co Ltd
Original Assignee
Biohaven Pharmaceutical Holding Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Pharmaceutical Holding Co Ltd filed Critical Biohaven Pharmaceutical Holding Co Ltd
Publication of CA3025019A1 publication Critical patent/CA3025019A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3025019A 2016-05-20 2017-05-19 Use of glutamate modulating agents with immunotherapies to treat cancer Pending CA3025019A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662339433P 2016-05-20 2016-05-20
US62/339,433 2016-05-20
PCT/US2017/033690 WO2017201502A1 (en) 2016-05-20 2017-05-19 Use of glutamate modulating agents with immunotherapies to treat cancer

Publications (1)

Publication Number Publication Date
CA3025019A1 true CA3025019A1 (en) 2017-11-23

Family

ID=60326148

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3025019A Pending CA3025019A1 (en) 2016-05-20 2017-05-19 Use of glutamate modulating agents with immunotherapies to treat cancer

Country Status (26)

Country Link
US (4) US11400155B2 (https=)
EP (3) EP3458053B1 (https=)
JP (4) JP7169195B2 (https=)
KR (2) KR102525527B1 (https=)
CN (2) CN109890387B (https=)
AU (2) AU2017266951B2 (https=)
CA (1) CA3025019A1 (https=)
CY (1) CY1124999T1 (https=)
DK (2) DK3458053T3 (https=)
EA (1) EA201892587A1 (https=)
ES (3) ES2905823T3 (https=)
FI (1) FI4019019T3 (https=)
HR (2) HRP20240617T1 (https=)
HU (2) HUE058184T2 (https=)
IL (2) IL292302B2 (https=)
LT (2) LT4019019T (https=)
MX (2) MX2018013868A (https=)
PH (1) PH12018502409A1 (https=)
PL (2) PL3458053T3 (https=)
PT (2) PT4019019T (https=)
RS (2) RS62935B1 (https=)
SG (1) SG11201809669RA (https=)
SI (2) SI3458053T1 (https=)
SM (1) SMT202400174T1 (https=)
WO (2) WO2017201502A1 (https=)
ZA (1) ZA201807398B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138753A1 (en) * 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
RS62915B1 (sr) * 2015-03-03 2022-03-31 Biohaven Therapeutics Ltd Prolekovi riluzola i njihova primena
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
CN114591433A (zh) 2015-07-13 2022-06-07 西托姆克斯治疗公司 抗pd-1抗体、可活化抗pd-1抗体及其使用方法
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
WO2017201502A1 (en) * 2016-05-20 2017-11-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer
GB2567093A (en) 2016-07-15 2019-04-03 Viracta Therapeutics Inc Histone deacetylase inhibitors for use in immunotherapy
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
EP4491237A3 (en) * 2016-10-28 2025-03-26 Bristol-Myers Squibb Company Methods of treating urothelial carcinoma using an anti-pd-1 antibody
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2020023324A1 (en) * 2018-07-22 2020-01-30 Biohaven Therapeutics Ltd. Use of riluzole prodrugs to treat alzheimer's disease
JP2020522486A (ja) 2017-06-01 2020-07-30 サイトメックス セラピューティクス インコーポレイテッド 活性化可能抗ｐｄｌ１抗体、およびその使用方法
EP3672990A1 (en) 2017-08-25 2020-07-01 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
EP3703822A4 (en) * 2017-11-03 2021-11-10 Calithera Biosciences, Inc. CONJOINT THERAPY WITH GLUTAMINASE INHIBITORS
JP2021514379A (ja) 2018-02-21 2021-06-10 ファイブ プライム セラピューティクス， インコーポレイテッド Ｂ７−ｈ４抗体製剤
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
AU2019223014B2 (en) 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
MA52416A (fr) 2018-03-02 2021-04-21 Five Prime Therapeutics Inc Anticorps b7-h4 et leurs procédés d'utilisation
EP3914266A4 (en) * 2019-01-24 2022-12-07 University of Cincinnati AUTOLOGOUS TUMORORGANOID AND IMMUNE CELL COCULTURES AND METHODS FOR USE AS PREDICTIVE MODELS FOR TREATMENT OF PANCREA CANCER
US20220304984A1 (en) * 2019-06-12 2022-09-29 Vanderbilt University Amino acid transport inhibitors and the uses thereof
CN110646557A (zh) * 2019-10-12 2020-01-03 北京航空航天大学 携带idh基因突变的胶质母细胞瘤患者的尿液代谢标志物及其用途
CA3175322A1 (en) * 2020-03-17 2021-09-23 Ohio State Innovation Foundation Designer extracellular vesicles for treating excitotoxicity
KR102441650B1 (ko) * 2020-07-31 2022-09-08 서울대학교병원 다중약물 화학요법에 있어서 항암제의 유효 용량 정보의 제공 방법
WO2022197767A1 (en) * 2021-03-17 2022-09-22 Memorial Sloan-Kettering Cancer Center Methods for improving survival in lung cancer patients via ketamine oncoprotection
WO2023003972A1 (en) * 2021-07-21 2023-01-26 Viracta Subsidiary, Inc. Cancer treatment combinations
TW202406539A (zh) * 2022-04-21 2024-02-16 大陸商北京加科思新藥研發有限公司 藥物組合及其用途
CN116492322A (zh) * 2023-05-10 2023-07-28 徐州医科大学 小分子阻滞剂mem在制备治疗肿瘤药物的应用
CN119174765A (zh) * 2024-09-04 2024-12-24 复旦大学附属中山医院 Gsdme蛋白的小分子抑制剂在肿瘤及其免疫治疗中的作用

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7812A (en) 1850-12-03 Nail-plate feeder and turner
US135A (en) 1837-03-03 Jesse j
CA209066A (en) 1921-03-01 Tschirner Frederick Conversion of potassium to soluble state
US6355476B1 (en) 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
US6362325B1 (en) 1988-11-07 2002-03-26 Advanced Research And Technology Institute, Inc. Murine 4-1BB gene
US6303121B1 (en) 1992-07-30 2001-10-16 Advanced Research And Technology Method of using human receptor protein 4-1BB
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5631023A (en) 1993-07-09 1997-05-20 R.P. Scherer Corporation Method for making freeze dried drug dosage forms
US5457895A (en) 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
US5837287A (en) 1994-10-28 1998-11-17 R P Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
RU2192281C2 (ru) 1996-10-11 2002-11-10 Бристол-Маерс Сквибб Компани Способы и композиции для иммуномодуляции
AU736912B2 (en) 1997-02-20 2001-08-02 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
DE69834255T2 (de) 1997-07-25 2006-09-28 Alpex Pharma S.A. Verfahren zur herstellung eines granulates, geeignet zur herstellung schnell-freisetzender, im mund löslicher tabletten
SK288117B6 (sk) 1998-11-20 2013-09-03 Skyepharma Canada Inc. Rapidly dispersing solid dry therapeutic dosage form
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
EP1191944A2 (en) 1999-06-25 2002-04-03 Genentech, Inc. METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
US6284270B1 (en) 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
IL148079A0 (en) 1999-08-24 2002-09-12 Medarex Inc Human ctla-4 antibodies and compositions containing the same
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1261376A1 (en) 2000-01-27 2002-12-04 Genetics Institute, LLC Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US6814978B2 (en) 2000-12-29 2004-11-09 Mcneil-Ppc, Inc. Process for preparing a soft tablet
US6509040B1 (en) 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
AU2002334939A1 (en) 2001-10-12 2003-04-22 Eugene R. Cooper Compositions having a combination of particles for immediate release and for controlled release
EP1485296B1 (en) 2002-02-13 2011-07-20 Michael K. Weibel Drug dose - form and method of manufacture
SI1916001T1 (sl) 2002-03-04 2011-10-28 Imclone Llc Äśloveĺ ka protitelesa specifiäśna za kdr in njihova uporaba
PL375144A1 (en) 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
ES2393485T3 (es) 2003-07-02 2012-12-21 Innate Pharma Anticuerpos del receptor de NK pan-kir2dl y su uso en diagnóstico y terapia
US7803376B2 (en) 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
US7282217B1 (en) 2003-08-29 2007-10-16 Kv Pharmaceutical Company Rapidly disintegrable tablets
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP2287195B1 (en) 2004-07-01 2019-05-15 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
BR122020017756B1 (pt) 2004-08-26 2022-02-15 Pfizer Inc Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
ME01309B (me) 2004-08-26 2013-12-20 Pfizer Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza
US7972596B2 (en) 2004-11-18 2011-07-05 Imclone Llc Antibodies against vascular endothelial growth factor receptor-1
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
CN101103043A (zh) 2005-01-06 2008-01-09 诺和诺德公司 Kir结合剂和使用其的方法
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP1744020A1 (de) 2005-07-14 2007-01-17 Siemens Aktiengesellschaft Verfahren zum Starten einer Dampfturbinenanlage
AU2006301163B2 (en) 2005-10-14 2012-02-23 Innate Pharma Compositions and methods for treating proliferative disorders
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
KR101146852B1 (ko) 2005-12-05 2012-05-16 화이자 프로덕츠 인크. Ｃ?ｍｅｔ／ｈｇｆｒ 억제제의 다형체
DE602006018354D1 (de) 2005-12-05 2010-12-30 Pfizer Prod Inc Verfahren zur behandlung von abnormalem zellwachstum
JP2009521523A (ja) 2005-12-27 2009-06-04 ジュビラント・オルガノシス・リミテッド 口中溶解性医薬組成物およびその製造方法
CA2647282A1 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
US20100189723A1 (en) 2007-01-11 2010-07-29 Peter Andreas Nicolai Reumert Wagtmann Anti-kir antibodies, formulations, and uses thereof
JP2008278814A (ja) 2007-05-11 2008-11-20 Igaku Seibutsugaku Kenkyusho:Kk アゴニスティック抗ヒトｇｉｔｒ抗体による免疫制御の解除とその応用
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
CN101686942B (zh) 2007-06-27 2012-09-26 韩美药品株式会社 用于快速制备用于口服的崩解剂的方法及其产品
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
CA2700860C (en) 2007-10-01 2016-07-19 Jonathan A. Terrett Human antibodies that bind mesothelin, and uses thereof
ES2572356T3 (es) 2007-11-09 2016-05-31 Peregrine Pharmaceuticals Inc Composiciones de anticuerpos dirigidos contra VEGF y procedimientos
EA201000910A1 (ru) 2007-11-30 2011-04-29 Бристоль-Мейерз Сквибб Компани Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8485861B2 (en) 2008-10-31 2013-07-16 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US8788212B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8709411B2 (en) 2008-12-05 2014-04-29 Novo Nordisk A/S Combination therapy to enhance NK cell mediated cytotoxicity
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
EP3165540A1 (en) 2010-04-13 2017-05-10 Celldex Therapeutics, Inc. Antibodies that bind human cd27 and uses thereof
BR112012030711B1 (pt) 2010-05-31 2020-10-13 Ono Pharmaceutical Co. Ltd derivado de purinona
BR112013009086A2 (pt) * 2010-10-13 2016-07-26 Mustafa Bilgin Ali Djamgoz tratamento de câncer/inibição de metástase
CN106963947A (zh) 2010-11-22 2017-07-21 伊纳特医药股份有限公司 Nk细胞调节治疗和用于治疗血液恶性疾病的方法
CA2828940C (en) 2011-03-10 2024-04-16 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
SG10201603962TA (en) 2011-05-25 2016-07-28 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders
AU2012291744A1 (en) 2011-08-02 2014-02-20 Pfizer Inc. Crizotinib for use in the treatment of cancer
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
US9041556B2 (en) 2011-10-20 2015-05-26 Apple Inc. Method for locating a vehicle
SG11201401386XA (en) 2011-11-09 2014-10-30 Bristol Myers Squibb Co Treatment of hematologic malignancies with an anti-cxcr4 antibody
US10864271B2 (en) * 2012-02-15 2020-12-15 Rutgers, The State University Of New Jersey Combination therapy using riluzole to enhance tumor sensitivity to ionizing radiation
WO2013138753A1 (en) 2012-03-16 2013-09-19 Fox Chase Chemical Diversity Center, Inc. Prodrugs of riluzole and their method of use
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
WO2013192610A2 (en) 2012-06-23 2013-12-27 Fox Chase Chemical Diversity Center, Inc. Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
PL2904011T3 (pl) 2012-10-02 2018-01-31 Bristol Myers Squibb Co Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
SG11201601763SA (en) 2013-09-20 2016-04-28 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
CN103536594A (zh) * 2013-10-21 2014-01-29 江苏亚虹医药科技有限公司 G蛋白偶联受体拮抗剂在用于制备治疗谷氨酸受体高表达肿瘤药物中的用途
JP6508785B2 (ja) 2013-10-25 2019-05-08 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
SG10201912986PA (en) 2014-05-28 2020-02-27 Agenus Inc Anti-gitr antibodies and methods of use thereof
ES2916923T3 (es) 2014-07-11 2022-07-06 Ventana Med Syst Inc Anticuerpos anti-PD-L1 y usos diagnósticos de los mismos
US10392444B2 (en) * 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
US20160073759A1 (en) * 2014-09-15 2016-03-17 Beauty Solutions Agency Inc. Nail covering
EP3215182B1 (en) * 2014-11-05 2023-01-04 The Regents of The University of California Combination immunotherapy
WO2016081637A1 (en) * 2014-11-18 2016-05-26 Maximum Fidelity Surgica Simulations, Llc Post mortem reconstitution of circulation
US20160140879A1 (en) * 2014-11-19 2016-05-19 David Hananel Anatomically correct movement or deformation of simulated bodily structures
RS62915B1 (sr) * 2015-03-03 2022-03-31 Biohaven Therapeutics Ltd Prolekovi riluzola i njihova primena
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
EP3355875B1 (en) 2015-10-01 2021-09-29 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
WO2017201502A1 (en) 2016-05-20 2017-11-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer

Also Published As

Publication number Publication date
AU2021221560A1 (en) 2021-09-16
EP3458053A4 (en) 2019-11-20
JP7169195B2 (ja) 2022-11-10
CN109890387B (zh) 2022-06-14
PH12018502409A1 (en) 2019-04-08
PT4019019T (pt) 2024-05-13
KR102369735B1 (ko) 2022-03-02
CY1124999T1 (el) 2023-01-05
LT3458053T (lt) 2022-02-25
US20190290619A1 (en) 2019-09-26
EP3458053B1 (en) 2021-12-08
ES2981830T3 (es) 2024-10-10
EP3458054A4 (en) 2019-10-02
JP2023012508A (ja) 2023-01-25
PL3458053T3 (pl) 2022-04-25
US20190175731A1 (en) 2019-06-13
EP4019019A1 (en) 2022-06-29
DK4019019T3 (da) 2024-05-06
IL262849A (en) 2018-12-31
KR20220029772A (ko) 2022-03-08
FI4019019T3 (fi) 2024-05-14
JP7224186B2 (ja) 2023-02-17
DK3458053T3 (da) 2022-02-21
CN109890387A (zh) 2019-06-14
IL292302B2 (en) 2023-10-01
US12383619B2 (en) 2025-08-12
LT4019019T (lt) 2024-06-25
JP7493569B2 (ja) 2024-05-31
AU2017266951A1 (en) 2018-11-22
SG11201809669RA (en) 2018-11-29
ES2905823T3 (es) 2022-04-12
IL262849B (en) 2022-05-01
EP4019019B1 (en) 2024-02-07
AU2017266951B2 (en) 2021-05-27
HRP20220237T1 (hr) 2022-04-29
KR20190009334A (ko) 2019-01-28
HUE066655T2 (hu) 2024-08-28
SI3458053T1 (sl) 2022-04-29
AU2021221560B2 (en) 2023-10-26
IL292302B1 (en) 2023-06-01
BR112018073781A2 (pt) 2019-02-26
EP3458053A1 (en) 2019-03-27
JP2019516712A (ja) 2019-06-20
EA201892587A1 (ru) 2019-04-30
JP2019516711A (ja) 2019-06-20
RS65474B1 (sr) 2024-05-31
IL292302A (en) 2022-06-01
MX2018013868A (es) 2019-02-21
US20230310595A1 (en) 2023-10-05
ZA201807398B (en) 2020-05-27
CN115350263A (zh) 2022-11-18
US11400155B2 (en) 2022-08-02
RS62935B1 (sr) 2022-03-31
HRP20240617T1 (hr) 2024-07-19
SMT202400174T1 (it) 2024-07-09
US20250360208A1 (en) 2025-11-27
KR102525527B1 (ko) 2023-04-24
SI4019019T1 (sl) 2024-07-31
EP3458054B1 (en) 2022-02-23
WO2017201502A1 (en) 2017-11-23
EP3458054A1 (en) 2019-03-27
WO2017201501A1 (en) 2017-11-23
HUE058184T2 (hu) 2022-07-28
JP2022191256A (ja) 2022-12-27
MX2022010377A (es) 2022-09-21
PT3458053T (pt) 2022-02-01
PL4019019T3 (pl) 2024-07-01
JP7653398B2 (ja) 2025-03-28
ES2912131T3 (es) 2022-05-24

Similar Documents

Publication Publication Date Title
US20250360208A1 (en) Use of glutamate modulating agents with immunotherapies to treat cancer
US20250011466A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
TWI707692B (zh) 用於治療非小細胞肺癌之抗ｂ７-ｈ１及抗ｃｔｌａ-４抗體
US20240174749A1 (en) Methods of treating cancer with antibodies against tim3
BR112016024972B1 (pt) Anticorpo monoclonal humanizado, polinucleotídeo isolado,plasmídeo, composições farmacêutica e de disgnóstico, usos do dito anticorpo monoclonal humanizado e método in vitro para determinar a expressão de ceacam1
HK40006436B (en) Use of glutamate modulating agents with immunotherapies to treat cancer
HK40006436A (en) Use of glutamate modulating agents with immunotherapies to treat cancer
EA049786B1 (ru) Использование глутамат-модулирующих средств вместе с иммунотерапией для лечения рака
EA041901B1 (ru) Использование глутамат-модулирующих средств вместе с иммунотерапией для лечения рака
BR112018073781B1 (pt) Composição farmacêutica compreendendo agentes anticâncer imunoterapêutico e de modulação de glutamato, kit e uso para o tratamento de câncer
HK1235023B (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer
HK1235023A1 (en) Anti-b7-h1 and anti-ctla-4 antibodies for treating non-small cell lung cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210520

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240806

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241101

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250123

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250425

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250430

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250522

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250522

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401